Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Irem Oner"'
Autor:
Muhammet Bekir Hacioglu, Bulent Erdogan, Murat Bardakcı, Efnan Algın, Burcu Gulbagcı, Ilhan Hacibekiroglu, Jamshid Hamdard, Omer Fatih Olmez, Hadi Akkus, Berna Oksuzoglu, Sema Sezgin Goksu, Shute Ailia Dae, Ahmet Taner Sumbul, Muzaffer Ugraklı, Mustafa Karaagac, Elif Sahin, Devrim Cabuk, Ozden Ozer, Tugba Yavuzsen, Rukiye Arıkan, Osman Köstek, Muhammed Mustafa Atcı, Abdullah Sakin, Adem Deligonul, Duygu Bayır, Murat Dincer, Oktay Unsal, Ozan Yazıcı, Esra Zeynelgil, Ahmet Gulmez, Hakan Harputluoglu, Cihan Erol, Mehmet Ali Nahit Sendur, Aydin Aytekin, Baran Akagunduz, Irem Oner, Ozlem Er, Bugra Oztosun, Mahmut Gumus, Fatih Selcuk Biricik, Musa Baris Aykan, Nuri Karadurmus, Ezgi Degerli, Nebi Serkan Demirci, Esma Turkmen, Teoman Şakalar, Saban Secmeler, Ozgur Tanrıverdi, Ali Alkan, Yasemin Kemal, Ibrahim Cil, Caglar Unal, Yakup Iriagaç, Ozkan Alan, Sevinc Balli, Yuksel Urun, Erkan Ozcan, Nazım Serdar Turhal, Irfan Cicin
Publikováno v:
Head & Neck.
Background: Most of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data. Methods: A total of 37 medica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79529589697c134a903b09e8faaa6c1f
https://doi.org/10.1002/hed.27376
https://doi.org/10.1002/hed.27376
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background This study aimed to establish risk groups on the basis of CPS-EG scores, independent of pCR status, in triple-negative breast cancer (TNBC) patients receiving neoadjuvant chemotherapy (NACT) to identify the prognostic impact of th
Externí odkaz:
https://doaj.org/article/6f27287556b24ac09fa0b818fc18e00c
Autor:
Bediz Kurt İnci, Pınar Kubilay Tolunay, Şura Öztekin, Ergin Aydemir, İrem Öner, Öztürk Ateş, Cengiz Karaçin
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 5722-5729 (2024)
Background: Currently, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy is a first-line treatment for hormone-receptor-positive and HER2-negative metastatic breast cancer. This study aimed to assess the impact
Externí odkaz:
https://doaj.org/article/a433ba64f8604e4fafa1869340c79037
Autor:
Pervin Ozkan Kurtgoz, Fatih Sackan, Irem Oner, Ozlem Bilgin, Deniz Ozdemir, Suleyman Karakose, Mehmet Ali Eryılmaz, Ibrahim Guney, Muhammet Cemal Kızılarslanoglu
Publikováno v:
Therapeutic Apheresis and Dialysis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cdfadd2b65842efdb3dc5400bc4442d1
https://doi.org/10.1111/1744-9987.13971
https://doi.org/10.1111/1744-9987.13971
Autor:
Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall survival (OS) compared to placebo. In rea
Externí odkaz:
https://doaj.org/article/7d19cca4236d429b8424cc6bef6070f5
Autor:
Elif Şenocak Taşçi, Basak Oyan, Ozlem Sonmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Irem Oner, Havva Yesil Cinkir, Melek Karakurt Eryılmaz, Onur Yazdan Balçık, Nail Paksoy, Derya Kivrak Salim, Mirac Özen, Melike Ozcelik, Ali Arican, Ali Inal, Baran Akagunduz, Dinçer Aydın, Leyla Ozer, Nazim Serdar Turhal, Ahmet Gulmez
Publikováno v:
Journal of Clinical Oncology. 40:202-202
202 Background: The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib (Reg) revealed promising results by improving overall survival compared to best supportive care. However, in real-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53bafb1d3de0a410579a00fc45d7f57e
https://doi.org/10.1200/jco.2022.40.4_suppl.202
https://doi.org/10.1200/jco.2022.40.4_suppl.202
Autor:
Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/3738f873f38f42ca820c7d9a886f1eba
Autor:
Tezer Kutluk, Mehmet Koç, İrem Öner, İbrahim Babalıoğlu, Meral Kirazlı, Sinem Aydın, Fahad Ahmed, Yavuz Köksal, Hüseyin Tokgöz, Mustafa Duran, Richard Sullivan
Publikováno v:
Conflict and Health, Vol 16, Iss 1, Pp 1-10 (2022)
Abstract Background With more than 3.6 million Syrian refugees Turkey hosts the world's largest number of Syrians. Considering the morbidity, mortality, and healthcare spending, cancer is one of the leading health and economic burden for patients and
Externí odkaz:
https://doaj.org/article/18bc66232df14d9d84c1ba97903c4f6d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Oncological Sciences, Vol 3, Iss 2, Pp 92-95 (2017)
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated. The most common adverse events report
Externí odkaz:
https://doaj.org/article/b8bebdaee9f94a4884c246843f7995d4